


## CERTIFICATE OF ANALYSIS

Compound	CJC-1295 with DAC
Pack size	5 mg
Batch identifier	PR-CJC-2604-001
Manufacturing date	2026-04-10
Testing date	2026-04-18
Testing laboratory	Independent third-party Australian laboratory

**1. HPLC PURITY (REVERSED-PHASE, UV 220 NM)**

Method: Reversed-phase high-performance liquid chromatography on a C18 column. Mobile phase: gradient acetonitrile in water with 0.1% trifluoroacetic acid. Detection at 220 nm. Purity reported as percent area under main peak relative to total integrated area.



**Result** 99.2% ( $\geq 98\%$  specification)

**2. MASS SPECTROMETRY (IDENTITY)**

Method	Electrospray ionisation mass spectrometry (ESI-MS)
Molecular formula	C <sub>152</sub> H <sub>252</sub> N <sub>44</sub> O <sub>42</sub>
Theoretical mass	3367.94 Da
Observed mass	3368.00 Da
Result	Identity confirmed

**3. ENDOTOXIN (LAL ASSAY)**

Method	Limulus amoebocyte lysate (LAL) chromogenic assay
Result	0.29 EU/mg (low-endotoxin specification)

#### 4. STORAGE AND HANDLING

Store lyophilised (unreconstituted) at 2–8 °C. Protect from light and moisture. Avoid repeated freeze–thaw cycles after reconstitution. Refer to the Pillar Research reconstitution and storage guide for full handling procedure.

#### REGULATORY STATUS

This compound is supplied for in vitro laboratory and educational research only. It is not listed on the Australian Register of Therapeutic Goods (ARTG) and is not a therapeutic good under the Therapeutic Goods Act 1989 (Cth). Not for human or animal consumption, therapeutic use, or diagnostic procedures. Research Use Only (RUO).

**Released by**  
QA Officer, Pillar Research  
Date: 2026-04-30

**Document control**  
Document: COA-CJC-1295-DAC  
Version: 1.0

SAMPLE — NOT FOR DISPA